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Abstract
The Bcr-Abl and Lyn protein tyrosine kinases have been separately linked to the emergence of
imatinib resistance in patients with chronic myelogenous leukemia. We have developed
fluorescent sensors for these kinases that are enzymatically and photophysically distinct, allowing
us to simultaneously, yet separately, visualize the tyrosine kinase activities of both Abl and Lyn.
Multicolor monitoring revealed that an imatinib resistant cell line (MYL-R) displays a remarkable
13-fold enhancement in Lyn kinase activity relative to its imatinib sensitive counterpart (MYL).
By contrast, both cell lines display nearly identical Abl activities. The upregulation of Lyn kinase
phosphotransferase activity in MYL-R cells is linked to an overexpression of the Lyn B isoform.
Furthermore, MYL-R cells possess a 4-fold higher level of activated Lyn and 5-fold lower level of
autoinhibited Lyn than MYL cells. Furthermore, studies with an activating SH2 ligand revealed
that Lyn from imatinib-resistant MYL-R cells is primed and active, whereas Lyn from imatinib-
sensitive cells is dependent upon phosphorylated SH2 ligands for activity.
Simultaneous monitoring of two or more biochemical events offers the means to establish,
in a temporally well-defined fashion, the influence of multiple effectors (e.g. second
messengers, enzymes, pathways) on cellular behavior (1–5). Several recent studies have
focused on the use of various green fluorescent protein (GFP) derivatives to construct pairs
of Förster resonance energy transfer (FRET) sensors (6–9). A number of challenges have
emerged in this regard, including the wide (and therefore overlapping) spectral width of the
fluorescent proteins as well as the limited dynamic range (<40%) of the fluorescent
response. Although GFP-based sensors are routinely employed in established cell lines, their
application to primary cells is challenging and their use in non-cellular systems (e.g. lysates,
pure enzymes, etc) would require purification and characterization of the protein construct.
Many “small molecule” sensors offer a dynamic range that significantly exceeds what is
possible via FRET, thereby providing an enhanced signal-to-noise ratio and thus reducing
the amount of sensor required (i.e. limiting the likelihood of a sensor-induced “observer
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effect”) (10). Furthermore, the wide array of spectrally distinct synthetic fluorophores vastly
exceeds that of the GFP family (11). These properties, along with their ease of large-scale
preparation, have resulted in the cross-platform use of small molecule sensors in cell-,
lysate-, and enzyme-based studies. However, their application to multicolor sensing of
multiple protein kinases has not been, to the best of our knowledge, reported.
Multicolor sensing could be especially useful in the arena of medical diagnostics, where the
relative activity of key enzymatic effectors and/or interacting pathways may furnish valuable
information regarding the design of therapeutic protocols. A case in point is the emergence
of imatinib (STI-571, Gleevec) resistance in chronic myelogenous leukemia (CML).
Imatinib has transformed the management of patients with CML, which is characterized by
expression of the deregulated protein tyrosine kinase Bcr-Abl (12). Although patients with
CML and other leukemias benefit from imatinib treatment, relapse following therapy is
common, particularly in individuals presenting advanced phase CML. Secondary mutations
in the Abl active site and amplification of the fused Bcr-Abl gene were initially identified as
the causative agents leading to resistance (13). However, abnormal activation of a Lyn
tyrosine kinase (Lyn)-mediated signaling pathway is now recognized to facilitate imatinib
resistance as well (13–18). Although Lyn inhibitors have received significant attention as
agents for the treatment of CML (19), enhanced Lyn kinase activity in imatinib-resistant
CML remains to be verified. Personalized medicine, which is based on the principle of a
tailor-made therapy targeting the individual patient’s needs, requires identification of the
aberrant enzymatic activity responsible for the disorder and subsequent application of drugs
that display the appropriate mechanism of action, potency, and selectivity. The latter
requires a robust diagnostic system, involving the simultaneous comparative analysis of
potential enzyme targets and the ability to screen therapeutic agents using the patient’s own
cells or lysates from these cells.
Peptide-based fluorescent sensors of protein kinase activity have been primarily employed
with purified enzymes, although a few examples of studies with lysates and intact cells have
been reported (20,21). In general, the phosphorylation-induced fluorescent changes in these
systems are driven by electrostatics associated with the negatively charged phosphate in the
phosphorylated product. The latter perturbs the photophysical properties of an
environmentally sensitive fluorophore, which is commonly excited at relatively short
wavelengths (<400 nm) or displays relatively modest extinction coefficients. Unfortunately,
fluorophores with photophysical properties such as these are generally inappropriate for cell-
based systems, including lysates. In addition, the sole reliance upon fluorophores excited at
less than 400 nm sharply compresses the spectral range and thus limits the ability to perform
multicolor sensing. By contrast, we’ve recently found that phosphorylation of tyrosine
mitigates the ability of this amino acid to serve as a fluorescent quencher, a phenomenon
that can be potentially applied to a large array of fluorophores irrespective of their emission
wavelengths (22). Based on this observation, we have now prepared a pair of orthogonal
Lyn and Abl sensors and have used these to assess the relative activity of their respective
enzymes from imatinib-resistant and-sensitive cell lines.
RESULTS AND DISCUSSION
Abl and Lyn Kinase Monitoring in CML
Two protein tyrosine kinases, namely Abl and Lyn, have been implicated in the mechanisms
responsible for imatinib resistance (13–19). The construction of orthogonal sensors for these
enzymes was fashioned using three specific attributes: (i) Lyn- and Abl-selective peptide
substrates, (ii) fluorophores with non-overlapping emission properties, and (iii) fluorophore-
peptide conjugates that respond to phosphorylation in a fluorescently sensitive fashion.
Although orthogonal peptide substrates for these two tyrosine kinases have not been
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previously described, their well-defined substrate sequence preferences suggested that it
should be possible to identify mutually exclusive substrates (21–23). Indeed, based upon
these preferences, we designed the two sequences present in 9 and 11 and assessed their
selectivity for their intended enzyme targets. Tyrosine is a known quencher of fluorescence
and we recently showed that this property is sharply curtailed upon phosphorylation (22).
The quenching mechanism proceeds via a dynamic collisional process (24), possibly
involving a phosphorylation-induced change in tyrosine’s redox potential (25).
Consequently, and in marked contrast to FRET-based fluorescence quenching, tyrosine’s
presumed mechanism of action should be independent of the excitation and emission
wavelengths of the fluorophore and thus applicable to an array of flurophores. Indeed, this
strategy had been successfully employed with a short wavelength fluorophore (pyrene) (22)
and, in this study, now extended to include mid (cascade yellow) and long (oxazine)
wavelength fluorophores. The dynamic range associated with these sensors (from 2 – 7-fold)
(22) is approximately an order of magnitude greater than what has been described for the
GFP FRET-based reporters (6,8,9). Furthermore, since previously described GFP-based
sensors are composed of two GFP proteins, each of which have broad excitation and
emission bands, much of the spectral bandwidth is occupied. Single fluorophore constructs,
with relatively narrow bandwidths, preserve spectral space for additional sensors.
Our sensors reveal that the imatinib resistant cell line MYL-R and its imatinib sensitive
counterpart MYL exhibit essentially identical Abl kinase activity, but markedly differ in
their Lyn kinase activity. In short, a significantly higher fraction of Lyn is primed and active
in the MYL-R versus MYL cell line. Furthermore, our studies reveal that although Lyn is
present as two isoforms, A and B, it is the latter that is dramatically up-regulated in MYL-R
cells.
Design of the Lyn/Abl sensor pair
Ac-Glu-Lys-Glu-Ile-Tyr-Gly-Glu-Ile-Glu-Ala-amide, where the Lys side chain serves as the
fluorophore attachment site and Tyr serves as the phosphoryl acceptor, is a sequence
phosphorylated by Lyn (22). As noted above, Tyr also acts as a fluorescent quencher. We’ve
previously noted that effective fluorescence quenching occurs when the fluorophore is
positioned on the third residue removed from the Tyr moiety (22). However, it occurred to
us that deeper quenching might be observed if the fluorophore were exposed to two
phosphorylatable tyrosine moieties. Consequently, we designed and synthesized the oxazine
fluorophore 8 [λex = 666 nm, λem = 682 nm, ε = 120,000 M−1 cm−1, Φ = 0.29; Fig. 1],
which contains two carboxylate moieties and therefore two attachment sites for the peptide
substrate. Oxazine 8 was prepared from the starting 1,2-dihydroquinoline 1 in seven steps
and subsequently doubly condensed with the Lys side chain of the active site-directed
peptide substrate to furnish the 1:2 fluorophore-peptide construct 9 (Fig. 2). The latter
displays a Lyn-mediated 3.3-fold increase in fluorescence (Fig. 3a). A corresponding mono-
carboxylate oxazine (λex = 667 nm, λem= 684 nm, ε = 118,000 M−1 cm−1, Φ = 0.27) was
also prepared (data not shown) and attached to the Lys side chain of the active site-directed
peptide to furnish the 1:1 fluorophore-peptide adduct 10. The latter also serves as a Lyn
substrate and displays a modestly reduced (relative to 9) 2.5-fold enhancement in
fluorescence in response to kinase-catalyzed phosphorylation.
The Abl sensor was derived from an Abl recognition motif, Gly-Gly-Ile-Tyr-Ala-Ala-Pro-
Phe-Lys-Lys-Lys-Ala (23). The Cascade Yellow fluorophore (ε = 25,000 cm−1 M−1, Φ =
0.56) possesses photophysical properties (λex = 400 nm and λem = 525 nm) distinct from
those of the oxazines. Abl-catalyzed phosphorylation of (Cascade Yellow)-Gly-Gly-Ile-Tyr-
Ala-Ala-Pro-Phe-Lys-Lys-Lys-Ala 11 (Fig. 2) induces a 2.2-fold enhancement in
fluorescence (Fig. 3b). Lyn-catalyzed phosphorylation is only detected (λem= 705 nm) with
the oxazine-modified peptide and Abl activity is only observed (λem= 525 nm) with the
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Cascade Yellow-modified peptide (Fig. 2a–b). The Abl kinase does not interfere with the
ability of Lyn to phosphorylate its sensor nor does the Lyn kinase impede Abl’s activity with
its designated sensor.
The inhibitory efficacy of imatinib and dasatinib
The observed IC50 of imatinib for Abl (0.48 ± 0.04 µM) is essentially the same as previously
reported values using a radioactive assay (Supplementary Figure 1a) (26). These initial
studies were performed at a non-physiological ATP concentration of 50 µM. Since the
mechanism of action of imatinib is competitive with respect to ATP, we anticipated a sharp
rise in IC50 (i.e. decrease in inhibitory efficacy) at a more physiologically relevant ATP
level (5 mM). Indeed, under these conditions, the IC50 of imatinib is approximately 40-fold
higher (19 ± 1 µM) (Supplementary Figure 1b). Furthermore, in contrast to previous studies
(26, 27), we find that imatinib does not significantly discriminate between Abl and Lyn at
either low (0.48 ± 0.04 µM versus 0.25 ± 0.02 µM, respectively) or normal (19 ± 1 µM
versus 55.0 ± 2.5 µM, respectively) ATP levels (Supplementary Figures 1c and 1d).
Dasatinib has recently received significant attention for the treatment of imatinib-resistant
CML (19). Indeed, dasatinib is a more potent inhibitor of both Lyn B and Abl than imatinib
(Supplementary Figures 1e–1h). At physiological ATP levels, dasatinib inhibits both Abl
(0.088 ± 0.003 µM) and Lyn (0.17 ± 0.03 µM) two orders of magnitude more potently than
imatinib (cf. 19 ± 1 µM and 55.0 ± 2.5 µM, respectively). As expected, at sub-physiological
ATP levels, dasatinib acts as an even more powerful inhibitor of Abl (0.047 ± 0.003 µM)
and Lyn (0.021 ± 0.004 µM). However, we do note that the effect of high:low ATP
concentration (2-fold for Abl and 8-fold for Lyn) is not quite as dramatic as that observed
with imatinib (40-fold for Abl and 20-fold for Lyn). We believe that this may be a
consequence of an exceptionally high affinity of desatinib for both Abl and Lyn, one that
cannot be accurately quantified, especially under low ATP conditions. In particular, others
have reported sub-nM IC50 values for dasatinib. However, in these instances, the
concentration of the kinase significantly exceeded that of dasatinib itself (26). Since the IC50
we obtained for Lyn at 50 µM ATP is nearly identical to the enzyme concentration
employed, this raises the possibility that only a fraction of the total enzyme present is in an
active, inhibitor-sensitive state. The latter was confirmed by western blot analysis for Tyr
416 (pY416), an autophosphorylation site required for Lyn kinase activity (Supplementary
Figure 2). Only 25% of the commercial enzyme is present in the catalytically active pY416
state.
Lyn and Abl kinase activity in MYL and MYL-R lysates
MYL is a previously described bone marrow mononuclear cell line derived from a 24-year-
old female CML patient (17). Prior studies reported that Lyn mRNA, protein, and
phosphoprotein, are overexpressed in MYL-R cells, an imatinib-resistant cell line sub-
cloned from MYL cells (17). We probed for Abl and Lyn activity in lysates from both the
sensitive and resistant cell lines. Both cell lines display similar Abl activity (Fig. 4a). We
note that near-complete removal of Abl from lysates via immunodepletion significantly
reduces Abl sensor activity, consistent with the notion that compound 11 serves as a
selective indicator of Abl activity in cell lysates (Supplementary Figure 4). In contrast to the
similar Abl kinase activity in both MYL and MYL-R cell lines, we found that MYL-R cells
display dramatically more Lyn kinase (~13-fold) activity than their MYL counterparts (Fig.
4b). Reassuringly, sensor 9 phosphorylation is lost in Lyn-immunodepleted MYL-R lysates,
directly demonstrating that sensor 9 is selective for Lyn kinase activity (Supplementary
Figure 3).
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Assessment of Lyn sensor efficacy in cell lysates
Since the activity of Lyn, but not Abl, differs in MYL and MYL-R cells, we focused our
attention on a more detailed assessment of the Lyn kinase sensor. HEK293 cells were
employed as a negative background expression system, since lysates from these cells (empty
pcDNA3.1 control vector) exhibit minimal activity toward sensor 9 (Fig. 5). By contrast,
lysates from cells transiently transfected with a plasmid encoding the wild type Lyn A or
Lyn B isoform (a splice variant missing residues 22–42) (28,29) phosphorylate sensor 9 in a
time-dependent fashion. The wild type enzyme can occupy an inactive conformation, in
which pY527 (Src numbering; Y508, LynA; Y487, LynB) is intramolecularly bound to the
SH2 domain of the kinase. Peptides containing pTyr embedded within an appropriate amino
acid sequence compete for the SH2 domain, thereby releasing the intramolecularly bound
phosphorylated residue, ultimately leading to enzyme activation (30). The SH2 ligand Ac-
pTyr-Glu-Glu-Ile-Glu dramatically increases the rate of peptide 9 phosphorylation in both
Lyn A and Lyn B transfected cells (Fig. 5). A slight enhancement over background is also
observed with lysates from the control-transfected cells, suggesting the presence of
endogenous kinases at minimally detectable levels that respond to the SH2 ligand.
Constitutively active mutants of Lyn A and B (Y508F and Y487F, respectively) are likewise
detectable. As expected, the phosphotransferase activity of these mutants is not enhanced by
pTyr-bearing peptides. Finally, expression of the corresponding inactive “kinase dead” (KD)
versions of Lyn A and B (K275E and K254E, respectively) fail to display sensor 9
phosphorylation activity above control-transfected cells (+/− SH2 ligand).
Lyn expression and activity in MYL and MYL-R
Western blot analysis revealed that MYL-R cells possess 50% more total Lyn (A + B) than
MYL cells, which is primarily due to a dramatic increase in Lyn B content (Fig. 6a). MYL-
R cells possess a 4-fold higher level of activated Lyn (pY416) and 5-fold lower level of
autoinhibited Lyn (pY527) than MYL cells. The SH2 ligand, Ac-pTyr-Glu-Glu-Ile-Glu,
enhances Lyn kinase activity 7-fold in MYL lysates, but only 2-fold in MYL-R lysates (Fig.
6b and Supplementary Figure 5). This reflects the relative amount of Lyn present in the
autoinhibited state in these cell lines. These results reveal that Lyn from imatinib-resistant
cells is primed and active, whereas Lyn from imatinib-sensitive cells is dependent upon
phosphorylated SH2 ligands for activity.
Conclusions and Outlook
We have constructed a pair of orthogonal Abl and Lyn sensors. Multiwavelength monitoring
revealed that Lyn, not Abl, activity is dramatically upregulated in an imatinib resistant cell
line. Furthermore, the extent of catalytic activation (13-fold) is even greater than what would
have been predicted on the basis of enhanced protein content alone (1.5-fold). The
simultaneous measurement of multiple protein kinases may prove useful in a diagnostic
setting since, as in the case of imatinib resistance, several enzymes are often implicated as
the potential biochemical trigger for aberrant cellular behavior. The latter should be feasible
using leukocytes purified from patient peripheral blood or bone marrow aspirates.
Furthermore, multicolor sensing of catalytic activity has therapeutic implications since the
majority of drugs that target protein kinases primarily interfere with catalytic activity.
Consequently, sensors that furnish an activity readout offer the means to assess the efficacy
of drug cocktails and dosing regimens, prior to therapy, using the patient’s own cells.
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Analytical grade reagents were purchased from Sigma-Aldrich or Fisher, except for 1H-
benzotriazolium 1-[bis(dimethylamino)methylene]-5-chlorohexafluorophosphate (1-),3-
oxide (HCTU), benzotriazole-1-yloxytrispyrrolidinophosphonium hexafluorophosphate
(PyBop), amino acids, and TGR resins, which were obtained from NovaBiochem. Amine-
reactive fluorophores were obtained from Aldrich or Invitrogen. The SH2 ligand, Ac-pTyr-
Glu-Glu-Ile-Glu, was purchased from Bachem. UV-vis spectra were measured using a
Biochrome Libra S22 spectrophotometer. Emission and excitation spectra were obtained
using a Horiba Jobin Yvon Fluorolog 3 spectrofluorometer at 23 °C. Quantum yields were
measured using indodicarbocyanine iodide as an internal standard. Solutions were not
deaerated because control experiments showed that oxygen did not quench the fluorescence
of these dyes, due perhaps to their short lifetimes. Mass spectra were obtained on an Applied
Biosystems API 2000 LC/MS/MS system. See Supporting Information for Mass Spectral
data. 1H and 13C NMR spectra were recorded on Bruker DRX-300 spectrometer. See
Supporting Information for NMR data. All operations with dyes were performed under dim
light. Flasks containing dyes were wrapped with aluminum foil. Chemical names for
compounds were obtaining using ChemDraw Ultra 7. Human CML cells (imatinib-sensitive
Myl and imatinib-resistant MylR) were a generous gift from Dr. Hideo Tanaka (Dept. of
Haematology and Oncology, Hiroshima University, Hiroshima, Japan). Cells were cultured
in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS;
Atlanta Biologicals) and 1% penicillin/streptomycin (P/S; Invitrogen). HEK 293 cells were
acquired from ATCC. Cells were cultured in DMEM medium (Invitrogen) supplemented
with 10% FBS and 1% P/S. Cells were grown in a humidified incubator at 37°C with 5%
CO2. The Lyn A and Lyn B expression constructs were a generous gift from Dr. Juan Rivera
(Mol. Immunol. and Inflammation Branch, NIH, Bethesda, MD). Constructs were cloned
from the pLenti6/V5 vector (Invitrogen) into the pCDNA3.1 vector (Invitrogen). Point
mutations were made in the Lyn A (K275E, Y508F) and Lyn B (K254E, Y487F) constructs
using the Quickchange Site-directed Mutagenesis Kit (Stratagene) according to the
manufacturer’s instructions. Expression vectors were introduced into HEK 293 cells by
Lipofectamine transfection (Invitrogen) according to the manufacturer’s instructions. 36 h
post-transfection cells were washed with PBS and pelleted; cells were stored at −80 °C until
experimentation.
Chemical synthesis. 4-(7-methoxy-2,2,4-trimethyl-2H-quinolin-1-yl)-butyric acid ethyl ester
(2)
A 500 mL round-bottom flask was set up with a magnetic stir bar, a reflux condenser, and a
nitrogen line. The flask was charged with 7-methoxy-2,2,4-trimethyl-1,2-dihydro-quinoline
1 (31) (43 g, 0.21 mol), ethyl 4-bromobutyrate (88 g, 0.44 mol), sodium iodide (11 g, 0.073
mol), acetonitrile (150 mL, 2.9 mol), and sodium carbonate (52 g, 0.48 mol). The flask was
heated at reflux with stirring for 72 h. The reaction mixture was filtered and the acetonitrile
was removed with a rotary evaporator. The unreacted starting compound was removed from
the product by vacuum distillation using an oil pump. The recovery of 7-methoxy-2,2,4-
trimethyl-1,2-dihydro-quinoline was 7 g (16%, b.p. 120–125°C, 0.7 Torr). The viscous




A 500 mL round-bottom, three-necked flask was set up with a nitrogen line, a mechanical
stirrer, and a thermometer. The flask was immersed in a salt-ice cooling bath and 4-(7-
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methoxy-2,2,4-trimethyl-2H-quinolin-1-yl)-butyric acid ethyl ester (2, 30 g, 0.09 mol) was
placed in the flask and the stirrer was started. Sulfuric acid (30 mL, 0.6 mol) was added
slowly to the flask over the course of about 5 min. The reaction mixture was then stirred for
additional 30 min with cooling. When the temperature inside the flask was about −10°C,
fuming sulfuric acid (17 mL, 0.18 mol, 30% of free SO3) was added quickly to the flask.
The stirring was continued and the flask was allowed to slowly warm up to room
temperature while in cooling bath. The reaction mixture was stirred for another 48 h at room
temperature. The reaction mixture was poured into a 2 L beaker containing 500 g of ice and
the beaker was immersed in a salt-ice cooling bath. The acid was neutralized with 10%
solution of sodium hydroxide in water until the pH of the reaction mixture was about 7. The
temperature of the reaction mixture was kept below 10 °C during the neutralization process,
at the end of which the product crystallized. The crystals were filtered using a Büchner
funnel, washed with 50 mL of ice-cold water, and air-dried. The crystals were placed in 2 L
flask equipped with reflux condenser and 1 L of 100% ethanol was added. The mixture was
stirred with heating until the ethanol started to boil and some of the solid material dissolved.
The mixture was filtered while still hot using a Buchner funnel. The crystals (Na2SO4
hydrate) were washed with three portions of 100 mL of hot ethanol. A combined filtrate
solution was evaporated using a rotary evaporator and the resultant white solid was dried




methanesulfonate (3, 22 g, 0.052 mol), methanol (250 mL, 6.2), and Pd on carbon (10%, 1.0
g) were added to a 1 L high pressure, heavy wall Parr hydrogenation bottle. The bottle was
attached to a high-pressure Parr hydrogenation apparatus and the system was evacuated
using a water aspirator and then filled with hydrogen gas. The evacuation/filling procedure
was repeated three more times. Then the system was filled with hydrogen at 50 psi pressure
and the shaker was activated. The bottle was shaken at room temperature for 4 h until
hydrogen consumption stopped. The remaining pressure was carefully released and the
catalyst was removed by vacuum filtration through a Celite pad. The solvent was removed
under vacuum to give the final product as a white solid. The yield was 20 g (90% yield).
Disodium 4-(7-methoxy-2,2-dimethyl-4-(sulfonatomethyl)-3,4-dihydroquinolin-1(2H)-
yl)butanoate) (5)
A 500 mL round-bottomed, one-necked flask was set up with a magnetic stir bar and a
reflux condenser. The flask was charged with sodium [1-(3-ethoxycarbonyl-propyl)-7-
methoxy-2,2-dimethyl-1,2-dihydro-quinolin-4-yl]-methane-sulfonate (4, 20 g, 0.05 mol),
sodium hydroxide (2.09 g, 0.0522 mol), and 100 mL water. The mixture was stirred with
heating (50°C) for 1 h and then cooled to room temperature. The solvent was removed under
vacuum and the solid was stirred with 100 mL of MeOH at reflux for 30 min. The hot
suspension was filtered, the solid was washed with hot methanol, and dried. The yield of the
final product (white solid) was 20 g (100% yield).
Disodium 4-[7-hydroxy-2,2-dimethyl-4-(sulfonatomethyl)-3,4-dihydroquinolin-1(2H)-
yl]butanoate (6)
A 250 mL round-bottomed, one-necked flask was set up with a magnetic stir bar, a reflux
condenser, and a nitrogen line. The flask was charged with disodium 4-(7-methoxy-2,2-
dimethyl-4-(sulfonatomethyl)-3,4-dihydroquinolin-1(2H)-yl)butanoate) (5, 12 g, 0.029 mol),
sodium iodide (10 g, 0.07 mol), and a solution of 9.0 M hydrogen bromide in water (70 mL).
The flask was flushed with nitrogen and then was heated at 105 °C (oil bath) with stirring
for 18 h. The reaction mixture was cooled to room temperature and the excess hydrobromic
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acid was removed using rotavap. To ensure a complete removal of the hydrobromic acid,
100 mL of water was added to the residue and the solvent was removed. The yellow solid
was dissolved in 50 mL of water and the solution was neutralized by addition of solid
sodium bicarbonate. The solvent was removed by vacuum and the solid was refluxed with
stirring with 500 mL of acetone overnight under nitrogen to remove sodium iodide and
sodium bromide that are soluble in acetone. The mixture was cooled to room temperature
and filtered. The solid was dried was washed with acetone and dried. The yield was 9.3 g
(80% yield) as a tan solid.
The 4-nitrophenyldiazenylphenol 7
Step 1. p-Nitroaniline (0.546 g, 0.00395 mol) was added to a 100 mL round-bottomed, one-
necked flask equipped with a magnetic stir bar and an addition funnel. 10 mL of 10% HCl
was added to the flask. The mixture was stirred at room temperature until a clear solution
formed, and then the flask was immersed in an ice-water bath. A solution of sodium nitrite
(0.273 g, 0.00395 mol) in 5 mL of water was added drop-wise to the flask with stirring.
When the addition was complete, the mixture was stirred for another 30 min at 0°C. Step 2.
Disodium 4-[7-hydroxy-2,2-dimethyl-4-(sulfonatomethyl)-3,4-dihydroquinolin-1(2H)-
yl]butanoate, 6) (1.59 g, 0.00395 mol) was added to a 250 mL conical flask, followed by 10
mL of 10% HCl. The flask was immersed in an ice-water cooling bath and stirring was
started. The solution of p-nitrophenyldiazonium salt (from step 1) was added to the flask in
small portions (1–2 mL) over the course of 10 min. The reaction mixture was stirred for 1 h
at 0°C. The precipitated red solid was filtered, washed with water (3×15 mL). The red solid
was placed in a 500 mL round-bottomed, one-necked flask equipped with a magnetic stirrer.
Water (150 mL) was added to the flask and the stirring was started. Solid sodium
bicarbonate (1.125 g) was added to the flask in five portions to avoid excessive foaming.
The solvent was removed using a rotary evaporator. The solid residue was re-dissolved in
methanol. The solution was filtered to remove inorganic salts and the methanol was
removed using a rotary evaporator to give a red solid. The residue was re-dissolved in 25
mL of water, and the volume was reduced to 10 mL using the rotary evaporator (this
operation was necessary to remove traces of methanol). The solution was frozen and




hydroquinolinium-4-yl)methanesulfonate) (7, 0.671 g, 0.00132 mol), disodium 4-[7-
hydroxy-2,2-dimethyl-4-(sulfonatomethyl)-3,4-dihydroquinolin-1(2H)-yl]butanoate) (6,
0.532 g, 0.00132 mol), and acetic acid (25 mL, 0.44 mol) were added to a 100 mL round-
bottomed, one-necked flask set up with a magnetic stir bar and a reflux condenser. The
reaction mixture was heated at reflux for 24 h. TLC showed complete consumption of
starting material and formation of deeply blue-colored product (SiO2, eluent: acetone-water
(1:1), Rf product = 0.1, Rf starting material = 0, and 0.4). The reaction mixture was
evaporated and the residue was dissolved in 50 mL of a mixture of acetone-water (4:1). The
solution was mixed with 10 g silica and the solvent was removed under vacuum. The dye/
silica mixture was loaded onto a silica column prepared in acetone. The column was eluted
with an acetone-water gradient (0 – 10%). The dye containing fractions were combined and
the solvent was removed using a rotary evaporator. NMR analysis showed the presence of
impurities, and the dye was further purified on a preparative RP HPLC column, which was
eluted with water and acetonitrile. (Program: 0 – 60 min 100% water, 60 – 120 min 10%
acetonitrile/90% water, 120 – 150 min 50% acetonitrile/50% water, 150 – 180 min 80%
acetonitrile/20% water, 180 – 200 min 100% water.) The dye eluted at 105–115 min. The
dye-containing fractions were combined and reduced in volume from about 120 mL to 10
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mL using a rotary evaporator. The dye solution was frozen and lyophilized. The yield of
pure dye (blue solid) was 100 mg (10% yield).
Peptide synthesis. Lyn Sensor Peptide (9)
The peptide-resin Ac-Glu(tBu)-Lys(Mtt)-Glu(tBu)-Ile-Tyr(tBu)-Gly-Glu(tBu)-Ile-Glu(tBu)-
Ala-amide-resin was synthesized using standard Fmoc peptide synthesis protocol [amino
acids 5 eq, HCTU 5 eq, DIPEA (N,N-diisopropylethylamine) 10 eq] as previously
described.(21) The side chains of Glu and Tyr were protected with t-Bu. The side chain of
Lys was protected with the acid sensitive 4-methyltrityl (Mtt) group.
Tetramethylfluoroform-amidinium (TFFH) (5 eq) and DIPEA (10 eq) were used to ensure
successful coupling of Fmoc-Lys(Mtt)-OH (5 eq) at the Y-3 position. After synthesis of the
peptide on the resin and subsequent acetylation of the N-terminus, the Mtt on Lys was
selectively removed with 2% TFA. The side chain deprotected Lys amine was reacted with
the doubly activated oxazine diacid 8 (oxazine 1 eq, PyBop 10 eq, DIPEA 20 eq) in DMF.
The peptide was cleaved with TFA:H2O:TIS (triisopropylsilane) in a ratio of 95:2.5:2.5, and
purified via HPLC.
Abl Sensor Peptide (11)
NH2-Gly-Gly-Ile-Tyr(tBu)-Ala-Ala-Pro-Phe-Lys(Boc)-Lys(Boc)-Lys(Boc)-Ala-amide-resin
was synthesized via a standard Fmoc peptide synthesis protocol using a Prelude automatic
peptide synthesizer from Protein Technology (amino acids 5 eq, HCTU 5 eq, DIPEA 10 eq).
The free N-terminus was reacted with Cascade Yellow succinimidyl ester (2 eq) and DIPEA
(4 eq) in DMF. The peptide was cleaved with TFA:H2O:TIS (triisopropylsilane) in a ratio of
95:2.5:2.5, and purified via HPLC.
Protein kinase assays
Assays were generally performed following a previously reported protocol (22) but with a
total volume of 25 µl from the following stock solutions: 10 µl H2O, 2.5 µL 0.1 mM peptide
stock solution, 2.5 µL 1M Tris (pH 7.5), 2.5 µL 200 mM MgCl2, 2.5 µL 0.1 mg mL−1 BSA,
0.5 µL 50 mM dithiothreitol (DTT), 2 µL 0.3 µM kinase and 2.5 µL 50 mM ATP. Final
concentration of the assay solution was: 100 mM Tris (pH 7.5), 0.01 mg mL−1 BSA, 1 mM
DTT, 24 nM kinase, 20 mM MgCl2, 5 mM ATP and 10 µM peptide sensor. Assays were
initiated either by adding ATP or peptide and the fluorescence was monitored using a
Gemini EM fluorescence microplate reader from Molecular Devices with 384-well
microplates at 30°C. Peptide 9: (λex = 665 nm; λem = 705 nm); Peptide 11: (λex = 400 nm;
λem = 525 nm). Dual monitoring of Abl and Lyn kinase activity was performed in an
analogous fashion, but in the presence of both 9 and 11, and either Abl or Lyn alone or in
combination. IC50 determinations were performed as described above with varying
concentrations of imatinib or dasatinib. Cell lysate assays were likewise performed as
described above using the following conditions: 100 mM Tris (pH 7.5), 5 mM ATP, 20 mM
MgCl2, 1/100 (volume) protease inhibitor cocktail (P8340, Sigma-Aldrich), 1/20
phosphatase inhibitor cocktail 2 (P5726, Sigma-Aldrich), 10 µM peptide sensor. Protein
concentration was determined using Bradford reagent (Thermo Scientific), and the
concentration of each sample was equilibrated to 2.5 µg µL−1 by addition of lysis buffer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank the National Institutes of Health (RO1-CA79954 and RO1-GM069976) for financial support.
Wang et al. Page 9














1. Ai HW, Hazelwood KL, Davidson MW, Campbell RE. Fluorescent protein FRET pairs for
ratiometric imaging of dual biosensors. Nat Methods. 2008; 5:401–403. [PubMed: 18425137]
2. Grant DM, Zhang W, McGhee EJ, Bunney TD, Talbot CB, Kumar S, Munro I, Dunsby C, Neil MA,
Katan M, French PM. Multiplexed FRET to image multiple signaling events in live cells. Biophys J.
2008; 95:L69–L71. [PubMed: 18757561]
3. Hu CD, Kerppola TK. Simultaneous visualization of multiple protein interactions in living cells
using multicolor fluorescence complementation analysis. Nat Biotechnol. 2003; 21:539–545.
[PubMed: 12692560]
4. Niino Y, Hotta K, Oka K. Simultaneous live cell imaging using dual FRET sensors with a single
excitation light. PLoS One. 2009; 4:e6036. [PubMed: 19551140]
5. Piljic A, Schultz C. Simultaneous recording of multiple cellular events by FRET. ACS Chem Biol.
2008; 3:156–160. [PubMed: 18355004]
6. Berrera M, Dodoni G, Monterisi S, Pertegato V, Zamparo I, Zaccolo M. A toolkit for real-time
detection of cAMP: insights into compartmentalized signaling. Handb Exp Pharmacol. 2008:285–
298. [PubMed: 18491057]
7. Ni Q, Titov DV, Zhang J. Analyzing protein kinase dynamics in living cells with FRET reporters.
Methods. 2006; 40:279–286. [PubMed: 16908183]
8. Palmer AE, Tsien RY. Measuring calcium signaling using genetically targetable fluorescent
indicators. Nat Protoc. 2006; 1:1057–1065. [PubMed: 17406387]
9. Tsien RY. Constructing and exploiting the fluorescent protein paintbox (Nobel Lecture). Angew
Chem Int Ed Engl. 2009; 48:5612–5626. [PubMed: 19565590]
10. Sharma V, Lawrence DS. Uber-responsive peptide-based sensors of signaling proteins. Angew
Chem Int Ed Engl. 2009; 48:7290–7292. [PubMed: 19739174]
11. Lavis LD, Raines RT. Bright ideas for chemical biology. ACS Chem Biol. 2008; 3:142–155.
[PubMed: 18355003]
12. Gora-Tybor J, Robak T. Targeted drugs in chronic myeloid leukemia. Curr Med Chem. 2008;
15:3036–3051. [PubMed: 19075651]
13. Breccia M, Alimena G. Resistance to imatinib in chronic myeloid leukemia and therapeutic
approaches to circumvent the problem. Cardiovasc Hematol Disord Drug Targets. 2009; 9:21–28.
[PubMed: 19275574]
14. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of
imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol
Chem. 2004; 279:34227–34239. [PubMed: 15175350]
15. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR-ABL independence
and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to
STI571. Blood. 2003; 101:690–698. [PubMed: 12509383]
16. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes
K, Kantarjian H, Talpaz M. Imatinib mesylate resistance through BCR-ABL independence in
chronic myelogenous leukemia. Cancer Res. 2004; 64:672–677. [PubMed: 14744784]
17. Ito T, Tanaka H, Kimura A. Establishment and characterization of a novel imatinib-sensitive
chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing
overexpression of Lyn. Eur J Haematol. 2007; 78:417–431. [PubMed: 17432977]
18. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz
M, Donato NJ. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and
persistent activation of LYN kinase. J Natl Cancer Inst. 2008; 100:926–939. [PubMed: 18577747]
19. Lee F, Fandi A, Voi M. Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem
Cell Biol. 2008; 40:334–343. [PubMed: 18401881]
20. Dai Z, Dulyaninova NG, Kumar S, Bresnick AR, Lawrence DS. Visual snapshots of intracellular
kinase activity at the onset of mitosis. Chem Biol. 2007; 14:1254–1260. [PubMed: 18022564]
21. Wang Q, Dai Z, Cahill SM, Blumenstein M, Lawrence DS. Light-regulated sampling of protein
tyrosine kinase activity. J Am Chem Soc. 2006; 128:14016–14017. [PubMed: 17061870]
Wang et al. Page 10













22. Wang Q, Cahill SM, Blumenstein M, Lawrence DS. Self-reporting fluorescent substrates of protein
tyrosine kinases. J Am Chem Soc. 2006; 128:1808–1809. [PubMed: 16464077]
23. Songyang Z, Carraway KL 3rd, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger
J, Hubbard SR, Smith DP, Eng C, et al. Catalytic specificity of protein-tyrosine kinases is critical
for selective signalling. Nature. 1995; 373:536–539. [PubMed: 7845468]
24. Wakata A, Cahill SM, Blumenstein M, Gunby RH, Jockusch S, Marti AA, Cimbro B, Gambacorti-
Passerini C, Donella-Deana A, Pinna LA, Turro NJ, Lawrence DS. A mechanistic design principle
for protein tyrosine kinase sensors: application to a validated cancer target. Org Lett. 2008;
10:301–304. [PubMed: 18085786]
25. Doose S, Neuweiler H, Sauer M. Fluorescence quenching by photoinduced electron transfer: a
reporter for conformational dynamics of macromolecules. ChemPhysChem. 2009; 10:1389–1398.
[PubMed: 19475638]
26. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY,
Heinrich MC, Deininger MW, Druker BJ. In vitro activity of Bcr-Abl inhibitors AMN107 and
BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer
Res. 2005; 65:4500–4505. [PubMed: 15930265]
27. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB.
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Nat Med. 1996; 2:561–566. [PubMed: 8616716]
28. Stanley E, Ralph S, McEwen S, Boulet I, Holtzman DA, Lock P, Dunn AR. Alternatively spliced
murine lyn mRNAs encode distinct proteins. Mol Cell Biol. 1991; 11:3399–3406. [PubMed:
1710766]
29. Yi TL, Bolen JB, Ihle JN. Hematopoietic cells express two forms of lyn kinase differing by 21
amino acids in the amino terminus. Mol Cell Biol. 1991; 11:2391–2398. [PubMed: 2017160]
30. Liu X, Brodeur SR, Gish G, Songyang Z, Cantley LC, Laudano AP, Pawson T. Regulation of c-Src
tyrosine kinase activity by the Src SH2 domain. Oncogene. 1993; 8:1119–1126. [PubMed:
7683128]
31. Rosowsky A, Modest EJ. 2,2,4-Trimethyl-1,2-dihydroquinolines. Preparation and Nuclear
Magnetic Resonance Studies. The Journal of Organic Chemistry. 1965; 30:1832–1837.
Wang et al. Page 11














Synthesis of the oxazine diacid 8. The latter was coupled to the Lys side chain of the Lyn
peptide substrate Ac-Glu-Lys-Glu-Ile-Tyr-Gly-Glu-Ile-Glu-Ala-amide, to furnish the 2:1
peptide:oxazine conjugate 9.
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Structures of the Lyn (9 and 10) and Abl (11) substrates.
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(a) Phosphorylation of 9 (λex = 665 nm, λem = 705 nm) by purified Lyn B (black), Lyn B/
Abl (blue), and Abl (green). (b) Phosphorylation of 11 (λex = 400 nm, λem = 525 nm) by
purified Lyn B (black), Lyn B/Abl (blue), and Abl (green).
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(a) Phosphorylation of the Abl sensor 11 (λex = 400 nm, λem = 525 nm) by MYL (red) and
MYL-R (blue) lysates. (b) Phosphorylation of the Lyn sensor 9 (λex = 665 nm, λem = 705
nm) by MYL lysates (red) MYL-R lysates (blue). Lysates contain all endogenous protein
kinases and were normalized for total protein content as described in the Methods Section
(Protein Kinase Assays). Abl and Lyn kinase activities were monitored simultaneously
during the course of the experiments.
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Initial rate of the phosphorylation of Lyn sensor 9 [without (unfilled) and with (filled) SH2
ligand (200 µM Ac-pTyr-Glu-Glu-Ile-Glu)] by HEK293 cells transfected with the indicated
constructs (where Ctl = control-transfected HEK293 cells). Lysates contain were normalized
for total protein content as described in the Methods Section (Protein Kinase Assays).
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(a) Total Lyn A and B, pY416, and pY527 content in MYL and MYL-R cell lines. (b) Initial
phosphorylation rate of Lyn sensor 9 with Lyn-precleared MYL lysates (black), MYL
lysates (blue), Lyn-precleared MYL-R lysates (green), and MYL-R lysates (red).
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